Abstract
Angiotensin-converting enzyme 2 (ACE2) and accessory proteases (TMPRSS2 and CTSL) are needed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular entry, and their expression may shed light on viral tropism and impact across the body. We assessed the cell-type-specific expression of ACE2, TMPRSS2 and CTSL across 107 single-cell RNA-sequencing studies from different tissues. ACE2, TMPRSS2 and CTSL are coexpressed in specific subsets of respiratory epithelial cells in the nasal passages, airways and alveoli, and in cells from other organs associated with coronavirus disease 2019 (COVID-19) transmission or pathology. We performed a meta-analysis of 31 lung single-cell RNA-sequencing studies with 1,320,896 cells from 377 nasal, airway and lung parenchyma samples from 228 individuals. This revealed cell-type-specific associations of age, sex and smoking with expression levels of ACE2, TMPRSS2 and CTSL. Expression of entry factors increased with age and in males, including in airway secretory cells and alveolar type 2 cells. Expression programs shared by ACE2+TMPRSS2+ cells in nasal, lung and gut tissues included genes that may mediate viral entry, key immune functions and epithelial–macrophage cross-talk, such as genes involved in the interleukin-6, interleukin-1, tumor necrosis factor and complement pathways. Cell-type-specific expression patterns may contribute to the pathogenesis of COVID-19, and our work highlights putative molecular pathways for therapeutic intervention.
Original language | English (US) |
---|---|
Pages (from-to) | 546-559 |
Number of pages | 14 |
Journal | Nature Medicine |
Volume | 27 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2021 |
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Fingerprint
Dive into the research topics of 'Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Nature Medicine, Vol. 27, No. 3, 03.2021, p. 546-559.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics
AU - The NHLBI LungMap Consortium
AU - The Human Cell Atlas Lung Biological Network
AU - Muus, Christoph
AU - Luecken, Malte D.
AU - Eraslan, Gökcen
AU - Sikkema, Lisa
AU - Waghray, Avinash
AU - Heimberg, Graham
AU - Kobayashi, Yoshihiko
AU - Vaishnav, Eeshit Dhaval
AU - Subramanian, Ayshwarya
AU - Smillie, Christopher
AU - Jagadeesh, Karthik A.
AU - Duong, Elizabeth Thu
AU - Fiskin, Evgenij
AU - Triglia, Elena Torlai
AU - Ansari, Meshal
AU - Cai, Peiwen
AU - Lin, Brian
AU - Buchanan, Justin
AU - Chen, Sijia
AU - Shu, Jian
AU - Haber, Adam L.
AU - Chung, Hattie
AU - Montoro, Daniel T.
AU - Adams, Taylor
AU - Aliee, Hananeh
AU - Allon, Samuel J.
AU - Andrusivova, Zaneta
AU - Angelidis, Ilias
AU - Ashenberg, Orr
AU - Bassler, Kevin
AU - Bécavin, Christophe
AU - Benhar, Inbal
AU - Bergenstråhle, Joseph
AU - Bergenstråhle, Ludvig
AU - Bolt, Liam
AU - Braun, Emelie
AU - Bui, Linh T.
AU - Callori, Steven
AU - Chaffin, Mark
AU - Chichelnitskiy, Evgeny
AU - Chiou, Joshua
AU - Conlon, Thomas M.
AU - Cuoco, Michael S.
AU - Cuomo, Anna S.E.
AU - Deprez, Marie
AU - Duclos, Grant
AU - Fine, Denise
AU - Fischer, David S.
AU - Ghazanfar, Shila
AU - Shepherd, Douglas P.
N1 - Funding Information: N.K. was a consultant to Biogen Idec, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Indaloo, Theravance, LifeMax, Three Lake Partners and Optikira and received nonfinancial support from MiRagen. All of these were outside the work reported herein. J.L. is a scientific consultant for 10x Genomics. A.R. is a cofounder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and a SAB member of Thermo Fisher Scientific, Syros Pharmaceuticals, Asimov and Neogene Therapeutics. O.R.-R. and A.R. are coinventors on patent applications filed by the Broad Institute to inventions relating to single-cell genomics applications, such as in PCT/US2018/060860 and US Provisional Application no. 62/745,259. A.K.S. received compensation for consulting and has SAB membership from Honeycomb Biotechnologies, Cellarity, Cogen Therapeutics, Orche Bio and Dahlia Biosciences. S.A.T. was a consultant at Genentech, Biogen and Roche in the last 3 years. F.J.T. reports receiving consulting fees from Roche Diagnostics and ownership interest in Cellarity. L.V. is founder of Definigen and Bilitech, two biotech companies using human pluripotent stem cells and organoid cultures for disease modeling and cell-based therapy. J.A.K. has received advisory board fees from Boehringer Ingelheim, and has research contracts with Genentech. E.S.L. serves on the Board of Directors for Codiak BioSciences and serves on the Scientific Advisory Board of F-Prime Capital Partners and Third Rock Ventures; he is also affiliated with several nonprofit organizations including serving on the Board of Directors of the Innocence Project, Count Me In and Biden Cancer Initiative, and the Board of Trustees for the Parker Institute for Cancer Immunotherapy. He has served and continues to serve on various federal advisory committees. J.L. is a scientific consultant for 10x Genomics. J.B., J.C., M.E.R. and S.A.M. are funded in part by a sponsored research agreement from Janssen Pharmaceuticals. A.S. is an employee of Johnson & Johnson. R.J.X. is a cofounder of Celsius Therapeutics and Jnana Therapeutics, and a consultant at Novartis. All other authors declare no competing interests. Funding Information: funding from NIH grant R01HL141380. G.H.K. and M.K. received funding from Horizon2020 HCA ‘discovAIR’ project (no. 874656). M.A.K. received funding from Howard Hughes Medical Institute, CZI and Wall Center for Pulmonary Vascular Disease. J.A.K. received funding from NIH grants R01HL145372 (J.A.K./N.E.B.) and K08HL130595 (J.A.K.) and the Doris Duke Charitable Foundation (J.A.K.). M.L. received funding from the ERC (614620). H.L. acknowledges funding from the National Research Foundation of Korea. S.A.M., J.C., A.S., M.E.L. and J.B. acknowledge support from a Stand Up to Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Cancer Reserach Grant (SU2C-AACR-DT23-17 to S. M. Dubinett and A.S.). Stand Up to Cancer is a division of the Entertainment Industry Foundation. S.A.M., J.C., M.E.L. and J.B. acknowledge funding from Sponsored Research Agreements with Janssen Pharmaceuticals. J.B. and J.C. acknowledge funding from the Department of Defense (W81XWH1410234). S. Leroy acknowledges funding from Horizon 2020 under grant no. 874656 (discovAIR). S. Linnarsson acknowledges funding from the Knut and Alice Wallenberg Foundation (2015.0041 and 2018.0172), the Erling-Persson Family Foundation (Human Developmental Cell Atlas) and the Swedish Foundation for Strategic Research (SB16-0065 and RIF14-0057). J.L. acknowledges funding from Horizon2020 under grant no. 874656 (discovAIR), the Knut and Alice Wallenberg Foundation (2018.0172) and the Erling-Persson Family Foundation (HDCA). B.D.M. is supported by NIH grant R01 HL133153. K.B.M. acknowledges funding from CZI grant 2017-174169 (5022), Wellcome Trust grants 206194/Z/17/Z and 211276/Z/18/Z, MRC grant MR/S035907/1 and Horizon2020 grant no. 874656 (discovAIR). A.V.M. acknowledges funding from NIH grants HL135124, AG049665 and AI135964 and grant number CZF2019-002438 from the CZI Foundation awarded to the HCA Lung Seed Network. M.C.N. acknowledges funding from from grant number CZF2019-002438 from the CZI Foundation awarded to the HCA Lung Seed Network, GSK, Netherlands Lung Foundation project nos. 5.1.14.020 and 4.1.18.226 and Horizon2020 under grant no. 874656 (discovAIR). M.Z.N. acknowledges funding from Rutherford Fund Fellowship allocated by the MRC and the UK Regenerative Medicine Platform (MR/5005579/1); Rosetrees Trust (grant no. M899). M.N. acknowledges funding from a BHF/DZHK grant and the BHF (PG/16/47/32156), CZI RFA CZF2019-002431e for Research Excellence and the Centre for Regenerative Medicine, Imperial College London. J.O.-M. acknowledges funding from the Richard and Susan Smith Family Foundation. G.Y.O. acknowledges support from the Canada Research Chair, the Canadian Institute of Health Research and the Heart and Stroke Foundation. D.P. acknowledges funding from the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center. S.R.Q. acknowledges funding from the CZI Biohub. J.R. acknowledges funding from LungMAP and CZI Seed Network. P.R.T. acknowledges funding from R01HL146557 from NHLBI/NIH and CZI-HCA Seed projects. E.L.R. acknowledges funding from the MRC (MR/S035907/1 and MR/P009581/1), Wellcome Trust (109146/Z/15/Z), Core support from the Wellcome Trust (203144/Z/16/Z) and Cancer Research UK (C6946/A24843). A.R. and O.R.-R. were supported by the Howard Hughes Medical Institute, the Klarman Cell Observatory, the Manton Foundation and the CZI. P.A.R. acknowledges funding from the NIH (K08HL146943), a Parker B. Francis Fellowship and an ATS Foundation/Boehringer Ingelheim Pharmaceuticals Research Fellowship in idiopathic pulmonary fibrosis. M.R. acknowledges funding from 1 U01 HL14555-01. K.S.‐P. acknowledges funding from NIHR Cambridge Biomedical Research Centre. C.S. acknowledges funding from the Swedish research Council, Swedish Cancer Society, CPI and Horizon2020 under grant no. 874656 (discovAIR). H.S. was supported by grant number CZF2019-002438 from the CZI Foundation awarded to the HCA Lung Seed Network, the German Center for Lung Research and Helmholtz Association, and Horizon2020 under grant no. 874656 (discovAIR). Work by J.S. was supported by J.L.S. funded in part by Boehringer Ingelheim, by the German Research Foundation (DFG; EXC2151/1, ImmunoSensation2-the immune sensory system; project nos. 390873048, 329123747 and 347286815) and by the HGF grant sparse2big. C.E.S. was supported by the Howard Hughes Medical Institute and the NIH (NHLBI; 2R01HL080494). J.G.S. was supported by the NIH (NHLBI; 2R01HL080494). A.K.S. was supported by the Beckman Young Investigator Program, a Sloan Fellowship in Chemistry, the NIH (5U24AI118672) and the Bill and Melinda Gates Foundation. D.P.S. was supported by the CZI Seed Network grant. J.R.S. is supported by the NHLBI (R01HL119215), by the NIAID Novel Alternative Model Systems for Enteric Diseases consortium (U19AI116482) and by grant no. CZF2019-002440 from the CZI DAF, an advised fund of Silicon Valley Community Foundation. F.J.T. was supported by grant no. CZF2019-002438 from the CZI Foundation awarded to the HCA Lung Seed Network, the Helmholtz Association’s Initiative and Networking Fund through Helmholtz AI (grant no. ZT-I-PF-5-01), Horizon2020 under grant no. 874656 (discovAIR) and the German Center for Lung Research. A.M.T. was supported by CZI Lung Atlas and National Science Foundation award no. IOS-2028295. L.V. was supported by the ERC advanced grant New-Chol, the Cambridge University Hospitals NIHR Biomedical Research Centre and the core support grant from the Wellcome Trust and MRC of the Wellcome–MRC Cambridge Stem Cell Institute. M.V.D.B. was supported by the Ministry of Economic Affairs and Climate Policy by means of the PPP. R.J.X. was supported by DK 043351, DK114784, AI142784 and DK117263. L.E.Z. was supported by the Agence Nationale de la Recherche (UCAJEDI, ANR-15-IDEX-01; SAHARRA, ANR-19-CE14-0027; France Génomique, ANR-10-INBS-09-03), Fondation pour la Recherche Médicale (DEQ20180339158), CZI (Silicon Valley Foundation, 2017-175159-5022) and Conseil Départemental des Alpes Maritimes (2016-294DGADSH-CV and 2019-390DGADSH-CV). D.Z. was supported by the MRC (MR/S035826/1) and ERC (614620). H.Z. is supported by the National Key R&D Program (2019YFA0801703) and the National Natural Science Foundation of China (31871370). This study was supported by NHLBI Molecular Atlas of Lung Development Program Human Tissue Core grants U01HL122700 and HL148861. J.W., G.H.D. and Y.X. acknowledge support from the NIH, U01 HL148856 LungMap Phase II–building a multidimensional map of developing human lung. X.S. and, A.W. acknowledge support from the NIH, 1U01 HL148867-01. Funding Information: We thank all donors, patients and their families for their contributions to the studies that are part of our integrated analysis. We thank L. Gaffney and A. Hupalowska for help with figure preparation, C. de Boer for critical reading of the manuscript and E. Spiegel from the statistical consulting core facility at the Institute of Computational Biology, Helmholtz Center Munich, for advice on statistical modeling. N.E.B. is supported by the National Institutes of Health (NIH)/NHLBI (R01HL145372) and the Department of Defense (W81XWH1910416). J.C. is supported by grants from the Medical Research Council (MRC; MR/S035826/1) and the European Research Council (ERC; 614620). R.E. and C.C. are supported by the European Commission (ESPACE/HEuropean Union Horizon 2020 Research and Innovation Program, 874710). T.D. is supported by HubMap consortium and Stanford Child Health Research Institute (Woods Family Faculty Scholarship). O.E. is supported by the Chan Zuckerberg Initiative (CZI) Seed Network and the NIH (1R01HL146519). C.S.F. is supported by DFG, SFB 738 project B3 (DFG FA-483/1-1). I.A.G. and the University of Washington Laboratory of Developmental Biology were supported by NIH award no. 5R24HD000836 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. A.G. is supported by a CZI Seed Network grant. P.H. acknowledges support from the LENDULET-BIOMAG grant (2018-342) and the CZI (CZF2019-002448). N.H. acknowledges support from a British Heart Foundation (BHF)/German Centre for Cardiovascular Research (DZHK) grant, ERC Advanced Grant under the Horizon 2020 Program and the Federal Ministry of Education and Research of Germany in the framework of CaRNAtion. W.J.J. received funding from the NIH (R35HL140039 and R01HL130938). N.K. received funding from NIH grants R01HL127349 and U01HL145567 and an unrestricted grant from Three Lakes Foundation. M.K. received Publisher Copyright: © 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2021/3
Y1 - 2021/3
N2 - Angiotensin-converting enzyme 2 (ACE2) and accessory proteases (TMPRSS2 and CTSL) are needed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular entry, and their expression may shed light on viral tropism and impact across the body. We assessed the cell-type-specific expression of ACE2, TMPRSS2 and CTSL across 107 single-cell RNA-sequencing studies from different tissues. ACE2, TMPRSS2 and CTSL are coexpressed in specific subsets of respiratory epithelial cells in the nasal passages, airways and alveoli, and in cells from other organs associated with coronavirus disease 2019 (COVID-19) transmission or pathology. We performed a meta-analysis of 31 lung single-cell RNA-sequencing studies with 1,320,896 cells from 377 nasal, airway and lung parenchyma samples from 228 individuals. This revealed cell-type-specific associations of age, sex and smoking with expression levels of ACE2, TMPRSS2 and CTSL. Expression of entry factors increased with age and in males, including in airway secretory cells and alveolar type 2 cells. Expression programs shared by ACE2+TMPRSS2+ cells in nasal, lung and gut tissues included genes that may mediate viral entry, key immune functions and epithelial–macrophage cross-talk, such as genes involved in the interleukin-6, interleukin-1, tumor necrosis factor and complement pathways. Cell-type-specific expression patterns may contribute to the pathogenesis of COVID-19, and our work highlights putative molecular pathways for therapeutic intervention.
AB - Angiotensin-converting enzyme 2 (ACE2) and accessory proteases (TMPRSS2 and CTSL) are needed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular entry, and their expression may shed light on viral tropism and impact across the body. We assessed the cell-type-specific expression of ACE2, TMPRSS2 and CTSL across 107 single-cell RNA-sequencing studies from different tissues. ACE2, TMPRSS2 and CTSL are coexpressed in specific subsets of respiratory epithelial cells in the nasal passages, airways and alveoli, and in cells from other organs associated with coronavirus disease 2019 (COVID-19) transmission or pathology. We performed a meta-analysis of 31 lung single-cell RNA-sequencing studies with 1,320,896 cells from 377 nasal, airway and lung parenchyma samples from 228 individuals. This revealed cell-type-specific associations of age, sex and smoking with expression levels of ACE2, TMPRSS2 and CTSL. Expression of entry factors increased with age and in males, including in airway secretory cells and alveolar type 2 cells. Expression programs shared by ACE2+TMPRSS2+ cells in nasal, lung and gut tissues included genes that may mediate viral entry, key immune functions and epithelial–macrophage cross-talk, such as genes involved in the interleukin-6, interleukin-1, tumor necrosis factor and complement pathways. Cell-type-specific expression patterns may contribute to the pathogenesis of COVID-19, and our work highlights putative molecular pathways for therapeutic intervention.
UR - http://www.scopus.com/inward/record.url?scp=85102367125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102367125&partnerID=8YFLogxK
U2 - 10.1038/s41591-020-01227-z
DO - 10.1038/s41591-020-01227-z
M3 - Article
C2 - 33654293
AN - SCOPUS:85102367125
SN - 1078-8956
VL - 27
SP - 546
EP - 559
JO - Nature Medicine
JF - Nature Medicine
IS - 3
ER -